Paclitaxel in Breast Cancer

Oncologist - United States
doi 10.1634/theoncologist.3-6-373
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Enriched Variations in TEKT4 and Breast Cancer Resistance to Paclitaxel

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2014English

Oral Paclitaxel in the Treatment of Metastatic Breast Cancer (MBC) Patients.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Quality-Adjusted Survival With Nab -Paclitaxel vs Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis

Clinical Breast Cancer
Cancer ResearchOncology
2018English

Nanomicellar Paclitaxel Increases Cytotoxicity of Multidrug Resistant Breast Cancer Cells

Cancer Letters
Cancer ResearchOncology
2009English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Molecular Predictors of Efficacy of Adjuvant Weekly Paclitaxel in Early Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2009English

Synergistic Interactions Between Aminoflavone, Paclitaxel and Camptothecin in Human Breast Cancer Cells

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2009English

TLR4 Is a Novel Determinant of the Response to Paclitaxel in Breast Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Paclitaxel-Induced Hypothermia and Hypoperfusion Increase Breast Cancer Metastasis and Angiogenesis in Mice

Oncology Letters
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy